Q3 2025 Omeros Corp Earnings Call Transcript
Key Points
- Omeros Corp (OMER) secured a significant deal with Novo Nordisk valued at up to $2.1 billion, providing substantial upfront and milestone payments.
- The company anticipates receiving $240 million in upfront cash from the Novo Nordisk deal, which will be used to repay existing debt and fund operations.
- Omeros Corp (OMER) is preparing for the commercial launch of Yartemlia, a treatment for transplant-associated thrombotic microangiopathy (TATMA), with a potential FDA approval expected by December 2025.
- The company has established a national ICD-10 diagnostic code and CPT procedural code for Yartemlia, positioning it as the only reimbursable TATMA treatment upon approval.
- Omeros Corp (OMER) is advancing a diversified pipeline, including MASP2, Oncology, TCAT, and PDE7 programs, targeting major unmet medical needs.
- Omeros Corp (OMER) reported a net loss of $30.9 million for the third quarter of 2025, an increase from the previous quarter.
- The company's cash burn for the quarter was $22 million, leaving $36.1 million in cash and investments as of September 30, 2025.
- There are risks and uncertainties associated with the forward-looking statements and regulatory approvals, which could impact the company's future performance.
- The company faces potential volatility in financial results due to non-cash mark-to-market adjustments on embedded derivatives tied to its debt.
- Omeros Corp (OMER) expects operating expenses to increase in the fourth quarter of 2025, primarily due to marketing costs associated with the anticipated launch of Yartemlia.
Good afternoon and welcome to today's earnings call for Omeros Corporation.
(Operator Instructions) Please be advised that this call is being recorded at the company's request. A replay will be available on the company's website for one week from today.
Now, I'll turn the call over to Jennifer Williams, Investor Relations for Omeros.
Thank you and good afternoon, everyone.
Before we begin, please note that today's discussion will include forward-looking statements. These statements reflect management's current expectations and beliefs as of today; and are subject to risks and uncertainties that could cause actual results to differ materially.
For a detailed discussion of these risks and uncertainties, please refer to the special note regarding forward-looking statements and the Risk Factor sections in our quarterly report on Form 10-Q, filed today with the SEC, as well as our most recent annual report on Form 10-K.
Today's call will include
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
